Individualized concurrent chemotherapy by pretreatment plasma Epstein‐Barr viral DNA in II‐III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort

Individualized concurrent chemotherapy by pretreatment plasma Epstein‐Barr viral DNA in II‐III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort

Abstract Object To ascertain the treatment effect of concurrent chemotherapy (CCT) in stage II‐III nasopharyngeal carcinoma (NPC) patients with different Epstein‐Barr virus (EBV) DNA level in intensity‐modulated radiotherapy (IMRT) era. Methods A total of 2742 patients diagnosed with stage II‐III NP...

Full description

Bibliographic Details
Main Authors: Xue‐Song Sun, Wen‐Hui Chen, Sai‐Lan Liu, Yu‐Jing Liang, Qiu‐Yan Chen, Shan‐Shan Guo, Yue‐Feng Wen, Li‐Ting Liu, Hao‐Jun Xie, Qing‐Nan Tang, Xiao‐Yun Li, Jin‐Jie Yan, Hai‐Qiang Mai, Lin‐Quan Tang
Format: Article
Language:English
Published: Wiley 2019-08-01
Series:Cancer Medicine
Subjects:
chemotherapy
Epstein‐Barr virus
nasopharyngeal carcinoma
overall survival
Online Access:https://doi.org/10.1002/cam4.2343

Internet

https://doi.org/10.1002/cam4.2343

Similar Items